Japanese recommendation moves alogliptin closer to the market
This article was originally published in Scrip
An advisory committee to Japan's ministry of health, labour and welfare has recommended for approval Takeda's oral antidiabetic, alogliptin. The positive opinion moves the DPP-4 inhibitor closer to what is likely to be its first market, following the delays in the US last year. Alogliptin has yet to be filed in Europe.
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.